ReviewCells2020
Kidney Organoids and Tubuloids.
Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 102 citations in OpenAlex.
- Synergistic innovation in organ-on-a-chip and organoid technologies: reshaping the future of disease modeling, drug development, and precision medicine.Protein & cell · 2026Review
- Redox control at the ER-mitochondria interface in kidney transplantation: MAM-centered stress signaling and translational organoid platforms.Redox biology · 2026Review
- Modelling kidney cystogenesis using human kidney tubuloid cultures.BMC molecular and cell biology · 2026Article
- Kidney Organoids in Drug Development: Integrating Technological Advances and Standardization for Effective Implementation.Advanced healthcare materials · 2026Review
- A Human Kidney Tubuloid Model of Repeated Cisplatin-Induced Cellular Senescence and Fibrosis for Drug Screening.Advanced healthcare materials · 2026Article
- Translational Potential: Kidney Tubuloids in Precision Medicine and Regenerative Nephrology.Pharmaceutics · 2026Article
- Stem cells in organogenesis and regeneration.Stem cell research & therapy · 2026Review
- Inflammasomes meet organoids and artificial intelligence: unraveling the complexity of gynecological inflammation.Frontiers in immunology · 2026Review
- Advances in Cytotoxicity Testing: From In Vitro Assays to In Silico Models.International journal of molecular sciences · 2025Review
- A Novel Human Distal Tubuloid-on-a-Chip Model for Investigating Sodium and Water Transport Mechanisms.Kidney360 · 2025Article
- A Robust Marine Collagen Peptide-Agarose 3D Culture System for In Vitro Modeling of Hepatocellular Carcinoma and Anti-Cancer Therapeutic Development.Marine drugs · 2025Article
- Human fetal kidney organoids model early human nephrogenesis and Notch-driven cell fate.The EMBO journal · 2025Article
- Recent advancements in patented technologies for the diagnosis and treatment of chronic kidney disease.International urology and nephrology · 2025Review
- Bioprinting of Alginate-Norbornene bioinks to create a versatile platform for kidneyBioactive materials · 2025Article
- Current status and future prospects of toxicity assessment using organoids.Toxicological research · 2025Review
- Insights into Modeling Inflammatory Bowel Disease from Stem Cell Derived Intestinal Organoids.Stem cell reviews and reports · 2025Review
- Kidney Fibrosis In Vitro and In Vivo Models: Path Toward Physiologically Relevant Humanized Models.Advanced healthcare materials · 2025Review
- Protective effects of N-acetylcysteine against titanium dioxide nanoparticles-induced kidney damage in rats.Journal of molecular histology · 2025Article
- Biomaterial-assisted organoid technology for disease modeling and drug screening.Materials today. Bio · 2025Review
- Genome-Based Advances in Modeling Renal Ciliopathies and Enhancing Patient Care.Kidney & blood pressure research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the past five years, pluripotent stem cell (PSC)-derived kidney organoids and adult stem or progenitor cell (ASC)-based kidney tubuloids have emerged as advanced in vitro models of kidney development, physiology, and disease. PSC-derived organoids mimic nephrogenesis. After differentiation towards the kidney precursor tissues ureteric bud and metanephric mesenchyme, their reciprocal interaction causes self-organization and patterning in vitro to generate nephron structures that resemble the fetal kidney. ASC tubuloids on the other hand recapitulate renewal and repair in the adult kidney tubule and give rise to long-term expandable and genetically stable cultures that consist of adult proximal tubule, loop of Henle, distal tubule, and collecting duct epithelium. Both organoid types hold great potential for: (1) studies of kidney physiology, (2) disease modeling, (3) high-throughput screening for drug efficacy and toxicity, and (4) regenerative medicine. Currently, organoids and tubuloids are successfully used to model hereditary, infectious, toxic, metabolic, and malignant kidney diseases and to screen for effective therapies. Furthermore, a tumor tubuloid biobank was established, which allows studies of pathogenic mutations and novel drug targets in a large group of patients. In this review, we discuss the nature of kidney organoids and tubuloids and their current and future applications in science and medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.